# IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

> **NCT05551507** · PHASE1,PHASE2 · RECRUITING · sponsor: **InxMed (Shanghai) Co., Ltd.** · enrollment: 150 (estimated)

## Conditions studied

- Platinum-resistant Ovarian Cancer

## Interventions

- **DRUG:** IN10018 in combination with PLD

## Key facts

- **NCT ID:** NCT05551507
- **Lead sponsor:** InxMed (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-07-27
- **Primary completion:** 2026-05-31
- **Final completion:** 2026-09-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05551507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05551507, "IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05551507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*